This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) (RACING)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01048671
First received: January 12, 2010
Last updated: October 29, 2015
Last verified: October 2015
Results First Received: December 23, 2013  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Condition: HIV Infections
Interventions: Drug: Raltegravir
Drug: ARV (non-raltegravir)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of 482 participants included in the trial, 2 were excluded from analysis. A single treatment arm was specified in the study, but participants were sub grouped by their prior ARV experience at Baseline (ARV naïve, suppressed, or virological failure) for analysis.

Reporting Groups
  Description
ARV naïve at Baseline ARV naïve participants had no previous experience with ARV. Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
Suppressed at Baseline Suppressed participants had previous ARV experience and had a viral load <50 ribonucleic acid (RNA) copies/mL at Baseline. Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
Virological Failure at Baseline Virological failure participants had previous ARV experience and had a viral load >50 RNA copies/mL at Baseline. Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.

Participant Flow:   Overall Study
    ARV naïve at Baseline   Suppressed at Baseline   Virological Failure at Baseline
STARTED   66   264   152 
COMPLETED   66   263   151 
NOT COMPLETED   0   1   1 
Protocol Violation                0                1                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ARV naïve at Baseline ARV naïve participants had no previous experience with ARV. Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
Suppressed at Baseline Suppressed participants had previous ARV experience and had a viral load <50 RNA copies/mL at Baseline. Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting. One participant in this subgroup was excluded from analysis because of protocol violation (inclusion criterion not met).
Virological Failure at Baseline Virological failure participants had previous ARV experience and had a viral load >50 RNA copies/mL at Baseline. Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting. One participant in this subgroup was excluded from analysis because of protocol violation (inclusion criterion not met).
Total Total of all reporting groups

Baseline Measures
   ARV naïve at Baseline   Suppressed at Baseline   Virological Failure at Baseline   Total 
Overall Participants Analyzed 
[Units: Participants]
 66   263   151   480 
Age 
[Units: Years]
Mean (Standard Deviation)
 42.9  (12.0)   47.3  (10.1)   46.5  (10.4)   46.4  (10.6) 
Gender 
[Units: Participants]
       
Female   17   91   65   173 
Male   49   172   86   307 
Time Since Human Immunodeficiency Virus (HIV) Infection Diagnosis 
[Units: Years]
Mean (Standard Deviation)
 2.8  (4.7)   13.0  (7.0)   11.6  (7.5)   11.1  (7.7) 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Receiving Antiretroviral Treatments Administered With Raltegravir   [ Time Frame: Up to 25 months after start of raltegravir treatment ]

2.  Primary:   Percentage of Participants Responding to Treatment: All Treated Participants   [ Time Frame: 24 months after start of raltegravir treatment ]

3.  Primary:   Percentage of Participants Responding to Treatment: Participants Still Receiving Raltegravir Treatment at Month 24   [ Time Frame: 24 months after start of raltegravir treatment ]

4.  Primary:   Mean Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count: All Treated Participants   [ Time Frame: Baseline and 24 months after start of raltegravir treatment ]

5.  Primary:   Mean Change From Baseline in CD4 Cell Count: Participants Still Receiving Raltegravir Treatment at Month 24   [ Time Frame: Baseline and 24 months after start of raltegravir treatment ]

6.  Secondary:   Number of Participants With at Least One Adverse Event   [ Time Frame: Up to 25 months after start of raltegravir treatment ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame No text entered.
Additional Description Two participants were excluded from the analysis because of protocol violation (inclusion criterion not met).

Reporting Groups
  Description
Antiretroviral Combination Therapy Including Raltegravir Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.

Serious Adverse Events
    Antiretroviral Combination Therapy Including Raltegravir
Total, Serious Adverse Events   
# participants affected / at risk   66/480 (13.75%) 
Blood and lymphatic system disorders   
ANAEMIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
FEBRILE BONE MARROW APLASIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
NEUTROPENIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Cardiac disorders   
ANGINA PECTORIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CARDIAC DISORDER † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CARDIAC FAILURE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CARDIO-RESPIRATORY ARREST † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CARDIOGENIC SHOCK † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CORONARY ARTERY STENOSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PERICARDIAL EFFUSION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Ear and labyrinth disorders   
DEAFNESS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Gastrointestinal disorders   
ASCITES † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
DIARRHOEA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
DIARRHOEA HAEMORRHAGIC † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
GASTROINTESTINAL HAEMORRHAGE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
INGUINAL HERNIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
INGUINAL HERNIA STRANGULATED † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   2 
NAUSEA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PANCREATITIS ACUTE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
VOMITING † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
General disorders   
ASTHENIA † 1   
# participants affected / at risk   2/480 (0.42%) 
# events   2 
CHEST PAIN † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
DEATH † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
GENERAL PHYSICAL HEALTH DETERIORATION † 1   
# participants affected / at risk   2/480 (0.42%) 
# events   2 
INFLUENZA LIKE ILLNESS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
MULTI-ORGAN FAILURE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
OEDEMA PERIPHERAL † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PAIN † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
SWELLING † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Hepatobiliary disorders   
CHOLESTASIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
HEPATIC CIRRHOSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   2 
Immune system disorders   
CRYOGLOBULINAEMIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
IMMUNE RECONSTITUTION SYNDROME † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Infections and infestations   
ABSCESS NECK † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
BRONCHOPNEUMONIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CANDIDA SEPSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CEREBRAL TOXOPLASMOSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CLOSTRIDIUM DIFFICILE COLITIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CYTOMEGALOVIRUS CHORIORETINITIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
HISTOPLASMOSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   2 
HISTOPLASMOSIS DISSEMINATED † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
LUNG INFECTION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
MENINGITIS VIRAL † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
MYCOBACTERIAL INFECTION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PNEUMOCYSTIS JIROVECI PNEUMONIA † 1   
# participants affected / at risk   2/480 (0.42%) 
# events   2 
POST PROCEDURAL INFECTION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PULMONARY SEPSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PYELONEPHRITIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
SEPSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
SEPTIC SHOCK † 1   
# participants affected / at risk   2/480 (0.42%) 
# events   2 
STAPHYLOCOCCAL INFECTION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
TOOTH INFECTION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Injury, poisoning and procedural complications   
ACCIDENT † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
ALCOHOL POISONING † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
DEVICE FAILURE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
FOOT FRACTURE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
HEAD INJURY † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
POST-TRAUMATIC PAIN † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Investigations   
BLOOD CREATINE PHOSPHOKINASE INCREASED † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
SCAN † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
TRANSAMINASES INCREASED † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
WEIGHT DECREASED † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Metabolism and nutrition disorders   
CACHEXIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
MALNUTRITION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   2 
MITOCHONDRIAL CYTOPATHY † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Musculoskeletal and connective tissue disorders   
ARTHRALGIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
FISTULA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
INTERVERTEBRAL DISC PROTRUSION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
MYALGIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
OSTEOPENIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
OSTEOPOROSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)   
CARCINOMA IN SITU † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CERVIX CARCINOMA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
ENDOMETRIAL CANCER † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
LYMPHOMA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   2 
NON-HODGKIN'S LYMPHOMA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
OROPHARYNGEAL CANCER STAGE UNSPECIFIED † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Nervous system disorders   
CEREBROVASCULAR ACCIDENT † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   2 
HEADACHE † 1   
# participants affected / at risk   3/480 (0.63%) 
# events   4 
HEMIPARESIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
ISCHAEMIC STROKE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Psychiatric disorders   
ANXIETY † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
DEPRESSION † 1   
# participants affected / at risk   5/480 (1.04%) 
# events   5 
LIBIDO DECREASED † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
NEGATIVE THOUGHTS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PARANOIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
SCHIZOPHRENIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
SUICIDE ATTEMPT † 1   
# participants affected / at risk   4/480 (0.83%) 
# events   4 
Renal and urinary disorders   
RENAL FAILURE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Reproductive system and breast disorders   
GYNAECOMASTIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PELVIC PAIN † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Respiratory, thoracic and mediastinal disorders   
ACUTE RESPIRATORY DISTRESS SYNDROME † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
ACUTE RESPIRATORY FAILURE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE † 1   
# participants affected / at risk   2/480 (0.42%) 
# events   2 
COUGH † 1   
# participants affected / at risk   2/480 (0.42%) 
# events   2 
DYSPNOEA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
HYPERCAPNIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
LUNG DISORDER † 1   
# participants affected / at risk   2/480 (0.42%) 
# events   2 
PLEURAL EFFUSION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PNEUMOTHORAX † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
RESPIRATORY FAILURE † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Skin and subcutaneous tissue disorders   
ANGIOEDEMA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
ECCHYMOSIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
LIPODYSTROPHY ACQUIRED † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PRURITUS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
RASH † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Surgical and medical procedures   
BENIGN TUMOUR EXCISION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
DENTAL OPERATION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
HERNIA REPAIR † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
INGUINAL HERNIA REPAIR † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
LEG AMPUTATION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   2 
PHLEBOTOMY † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PULMONARY VALVE REPLACEMENT † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
TOOTH EXTRACTION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Vascular disorders   
HYPERTENSION † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PERIPHERAL ISCHAEMIA † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
PHLEBITIS † 1   
# participants affected / at risk   1/480 (0.21%) 
# events   1 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 12.1




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@merck.com



Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01048671     History of Changes
Other Study ID Numbers: 0518-138
MK0518-138
Study First Received: January 12, 2010
Results First Received: December 23, 2013
Last Updated: October 29, 2015